School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Curr Diab Rep. 2024 Nov 12;25(1):4. doi: 10.1007/s11892-024-01557-z.
Supplementation of nicotinamide mononucleotides (NMN) has been claimed to improve metabolic function. We reviewed human randomised controlled trials (RCTs) of NMN to evaluate its effect on markers of glucose and lipid metabolism.
Eight RCTs on NMN (dosage ranged 250-2000 mg/d for a duration of 14 days to 12 weeks) involving a total of 342 middle-age/older adults (49% females, mainly non-diabetic) reporting at least one outcome on glucose control or lipid profile published in 2021-2023 were reviewed. The random-effects meta-analyses indicated no significant benefit of NMN on fasting glucose, fasting insulin, glycated hemoglobin, homeostatic model assessment for insulin resistance and lipid profile. Based on the small number of RCTs involving mainly relatively healthy adults, short-term supplementation of NMN of 250-2000 mg/d did not show significantly positive impacts on glucose control and lipid profile.
烟酰胺单核苷酸（NMN）的补充据称可以改善代谢功能。我们综述了 NMN 的人体随机对照试验（RCT），以评估其对葡萄糖和脂质代谢标志物的影响。
2021 年至 2023 年期间，共发表了 8 项关于 NMN 的 RCT 研究（剂量范围为 250-2000mg/d，持续时间为 14 天至 12 周），共纳入了 342 名中老年人（49%为女性，主要是非糖尿病患者），其中至少有一项关于葡萄糖控制或血脂谱的结果。基于对主要为相对健康成年人的少数 RCT 的分析，短期补充 250-2000mg/d 的 NMN 对葡萄糖控制和血脂谱没有显著的积极影响。
